BrightPath Biotherapeutics Co., Ltd
4594・Growth Market・Pharmaceuticals
Business
BrightPath Biotherapeutics Co., Ltd., founded in 2003, is a drug discovery venture specializing in cancer immunotherapy. The company holds multiple pipelines across two modalities—cell therapy (iPS-NKT cell therapy and CAR-T cell therapy) and antibody therapeutics (bispecific antibodies and T-cell engagers)—covering stages from exploratory research through early clinical trials. Its development approach is based on open innovation, built on collaborations with domestic and overseas academia and research institutions (RIKEN, Chiba University, Shinshu University, National Cancer Center, etc.), with its main customers being domestic and overseas pharmaceutical companies as out-licensing partners. The company is listed on the Growth Market of the Tokyo Stock Exchange.
Business Model
The company develops proprietary or in-licensed cancer immunotherapy drug candidates from exploratory research through early-stage clinical trials, then licenses them out to domestic and overseas pharmaceutical companies for late-stage clinical trials and beyond. Revenue consists of upfront payments at license contract execution, milestone payments tied to development progress, and sales royalties after launch. At present, there is no substantial sales revenue, and the structure relies on capital market fundraising through exercise of stock acquisition rights to cover R&D expenses.
Company Strengths
In November 2022, the company obtained an exclusive license from RIKEN for a patent (registered in Japan, the US, and Europe) that broadly and exclusively protects the use of allogeneic cell therapy derived from iPS cell-derived NKT cells. This forms a strong barrier to entry that can legally block competitors from entering with the same technology platform.
Results from the world's first Phase I clinical trial of iPS-NKT cell therapy (started June 2020, concluded January 2024), conducted at Chiba University, were published in Nature Communications on December 30, 2025. No issues were identified in the primary endpoints of tolerability and safety, and initial clinical activity, including cases of tumor growth suppression, was confirmed, providing internationally recognized scientific validation of the technology.
BP2202 (BCMA CAR-ipsNKT) was designated an orphan drug by the FDA in July 2025 for multiple myeloma. In addition to development incentives such as review fee exemptions and priority review, the IND application to the FDA has reached its final stage, confirming concrete progress toward the start of US clinical trials in FY2026 (ending March 2026).
ENVALITH's Perspective
Performance Trend
Revenue for FY2026 (ending March 2026) was ¥0 million (vs. ¥1 million in the prior period), remaining near zero as in the previous period. Selling, general and administrative expenses increased to ¥1,295 million (vs. ¥1,162 million in the prior period), leading to a wider operating loss. An impairment loss of ¥9 million associated with a change in the estimate of asset retirement obligations was recorded as an extraordinary loss. Operating cash outflow increased to ¥1,366 million (vs. ¥1,250 million in the prior period). For FY2027 (ending March 2027), the company forecasts an operating loss of ¥1,965 million as U.S. clinical trial expenses ramp up in earnest, indicating that the trend of widening losses is expected to accelerate. Regarding the external environment, the fundraising environment surrounding biotechnology companies continues to remain cautious, affected by domestic and overseas interest rate trends and changes in investors' risk appetite.
Growth Strategy
Aiming for clinical progress across multiple pipelines and realization of license-out deals, centered on the initiation of BP2202 (BCMA CAR-ipsNKT) clinical trials in the US
The IND application to the FDA is in its final stage, with US clinical trials planned to begin from FY2026 (ending March 2026). Orphan drug designation has already been obtained, granting review preferences. Manufacturing process transfer to Cellistic has also been completed, and preparations for the transition to clinical trials are in place.
The results of the Phase I clinical trial at Chiba University were published in Nature Communications (December 30, 2025 issue), demonstrating confirmed tolerability and safety along with initial clinical activity. This data will be leveraged as a platform for expansion into CAR-NKT cell therapeutics, aiming for deployment across a wide range of cancer types and regions.
BP1212 (anti-CD39 x anti-TIM-3 bispecific antibody) nonclinical data was presented at the IRCI conference in June 2025. BP1223 (CD39 x CD3 T-cell engager) results from joint research with National Cancer Center Hospital East were presented at the American Society of Hematology (ASH) annual meeting in December 2024. The company continues to aim for progress toward the development stage, where there is substantial licensing deal flow.
Through the issuance and exercise of the 17th to 20th stock acquisition rights, ¥2,737 million was raised in FY2026 (ending March 2026), securing a fiscal year-end cash balance of ¥2,156 million. In preparation for the expanded loss expected in FY2027 (ending March 2027) (forecast of ¥1,965 million), securing additional fundraising measures remains an ongoing challenge.
Last updated: July 19, 2026